Wedbush initiated coverage of Camp4 Therapeutics (CAMP) with an Outperform rating and $8 price target
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAMP:
- CAMP4 Therapeutics Unveils Promising Data at ASGCT 2025
- Camp4 Therapeutics delivers three presentantions on SYNGAP1-related disorders
- CAMP4 Therapeutics: Promising Pipeline and Strong Financials Justify Buy Rating
- Camp4 Therapeutics reports Q1 EPS (62c), consensus (70c)
- CAMP4 Therapeutics Advances RNA-Based Therapeutics